Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: A randomized eortc intergroup phase ii study (EORTC 40004)

Annals of Oncology

Volumn 23, Issue 10, 2012, Pages 2619-2626

  Ruers, T ^a   Punt, C ^b   Van coevorden, F ^a   Pierie, J P E N ^c   Borel Rinkes, I ^d   Ledermann, J A ^e   Poston, G ^f   Bechstein, W ^g   Lentz, M A ^h   Mauer, M ^h   Van Cutsem, E ⁱ   Lutz, M P ^j   Nordlinger, B ^k   Verwaal, V J ^l   Gruenberger, T ^m   Klaase, J ⁿ   Falk, S ^o   Wals, J ^p   Jansen, R L ^q   P Lindner ^r   Mulier, S ^s   Bosscha, K ^t   Jaeck, D ^u   Arnaud, J P ^v   Smith, D ^w   Sherlock, D ^x   Ammori, B ^y   Gillams, A ^z   El Serafi, M ^aa   Glimelius, B ^ab   Hellman, P ^ac   more..

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c MEDICAL CENTER LEEUWARDEN   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^g UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^h EORTC DATA CENTER   (Belgium)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j Caritasklinik St Theresia ^*  (Germany)

^k HÔPITAL AMBROISE PARÉ   (France)

^l NETHERLANDS CANCER INSTITUTE   (Netherlands)

^m MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁿ MEDISCH SPECTRUM TWENTE   (Netherlands)

^o BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^p Sittard Geleen Heerlen   (Netherlands)

^q MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^r SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^s UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^t JEROEN BOSCH HOSPITAL   (Netherlands)

^u HÔPITAL DE HAUTEPIERRE   (France)

^v ANGERS UNIVERSITY HOSPITAL   (France)

^w CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^x NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^y MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^z UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^aa NATIONAL CANCER INSTITUTE   (Egypt)

^ab KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^ac UPPSALA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Colorectal cancer; Liver metastases; Multimodality treatment; Radiofrequency ablation; Unresectable

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL EFFECTIVENESS; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIARRHEA; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; INOPERABLE CANCER; KIDNEY DISEASE; LIVER METASTASIS; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; SYSTEMIC THERAPY; TREATMENT OUTCOME;

EID: 84864129583     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds053     Document Type: Article

References (26)

1. House MG, Ito H, Gonen M et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg 2010; 210(5): 744-745.
2. Kopetz S, Chang GJ, Overman MJ et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27(22): 3677-3683.
3. Mitry E, Fields AL, Bleiberg H et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008; 26(30): 4906-4911.
4. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26(12): 2013-2019.
5. Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360(6): 563-572.
6. Van CE, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360(14): 1408-1417.
7. Sanoff HK, Sargent DJ, Campbell ME et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 2008; 26(35): 5721-5727.
8. de Baere T, Elias D, Dromain C et al. Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol 2000; 175(6): 1619-1625.
9. Martin RC, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol 2010; 17(1): 171-178.
10. Vogl TJ, Straub R, Eichler K et al. Colorectal carcinoma metastases in liver: laser-induced interstitial thermotherapy-local tumor control rate and survival data. Radiology 2004; 230(2): 450-458.
11. Abdalla EK, Vauthey JN, Ellis LM et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239(6): 818-825.
12. Gillams AR, Lees WR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 2009; 19(5): 1206-1213.
13. Mulier S, Ni Y, Jamart J et al. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg 2005; 242(2): 158-171.
14. Ruers TJ, Joosten JJ, Wiering B et al. Comparison between local ablative therapy and chemotherapy for non-resectable colorectal liver metastases: a prospective study. Ann Surg Oncol 2007; 14(3): 1161-1169.
15. Siperstein AE, Berber E, Ballem N, Parikh RT. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg 2007; 246(4): 559-565.
16. Crocetti L, de BT, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol 2010; 33(1): 11-17.
17. Gervais DA, Goldberg SN, Brown DB et al. Society of Interventional Radiology position statement on percutaneous radiofrequency ablation for the treatment of liver tumors. J Vasc Interv Radiol 2009; 20 (7 Suppl): S342-S347.
18. Wong SL, Mangu PB, Choti MA et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 2010; 28(3): 493-508.
19. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18(16): 2938-2947.
20. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92(3): 205-216.
21. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22(2): 229-237.
22. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23): 2335-2342.
23. Barone C, Nuzzo G, Cassano A et al. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer 2007; 97(8): 1035-1039.
24. Alberts SR, Horvath WL, Sternfeld WC et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005; 23(36): 9243-9249.
25. Ychou M, Viret F, Kramar A et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol 2008; 62(2): 195-201.
26. Nordlinger B, Sorbye H, Glimelius B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371(9617): 1007-1016.